Aymen Idris

I am a pharmacologist currently based at the University of Sheffield (England, UK). The focus of my research is the design and testing of novel anti-inflammatory agents. One of my particular areas of interests is the effect of cannabis-like substances on bone biology and pharmacology. In this area, I carried out significant research on the skeletal effects of endocannabinoids and their receptors on bone biology with publications in Nature Medicine, Cell Metabolism and Aging Cell. I also conduct research into the role of the NFkB signalling pathway in bone disease and I am a founder and CEO of arthElix Ltd. (est. 2017) and co-founder and shareholder of OsteoRX Ltd. (est. 2005), two start-up companies established to develop novel NFkB inhibitors as anti-rheumatic and anti-metastatic drugs. I am an avid supporter of issues and needs of early-career scientists, and founder of HubLE.org, held the first chair of the ECTS New Investigator Committee and founded the ECTS Postdoc Gathering and ECTS New Investigator Seminar. Besides science, I am involved in business activities related to my research, and his other passions include bicycle touring, playing the piano and writing.